Comparison of the effects of oral and intravenous acetylcysteine ??in treating acetaminophen poisoning

Comparison of the effects of oral and intravenous acetylcysteine ??in treating acetaminophen poisoning in admitted patients to poisoning emergency ward of Baharloo Hospital (2011-2012)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112218488N1

Enrollment

Registered

2013-05-10

Start date

2012-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acetaminophen Poisoning. Other nonopioid analgesics and antipyretics, not elsewhere classified

Interventions

Intervention 1: Standard (20-hour intravenous NAC protocol is 150 mg/kg loading dose over 15 minutes, followed by an additional dose of 50 mg/kg over 4 hours, and then 100 mg/kg over 16 hours, for a t

Treatment - Drugs

Standard (20-hour intravenous NAC protocol is 150 mg/kg loading dose over 15 minutes, followed by an additional dose of 50 mg/kg over 4 hours, and then 100 mg/kg over 16 hours, for a total dose 300 mg

Experimental group (The 72-hour oral regimen is a 140-mg/kg loading dose followed by 70 mg/kg for 17 additional doses, for a total dose of 1330 mg/kg.

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients over 18 years old age which admitted to toxicological emergency ward of Baharloo hospital in Tehran which consume 7.5 gr acetaminophen during 24 hr ago will be conclude in the study. Inclusion Criteria: Patients over 18 years old age; consumption 7.5 gr acetaminophen during 24 hr before admittion Exclusion Criteria: Admission after 24 hr after consumption of acetaminophen; Co ingestion of cholinergic drugs; Primary unconsciousness; Primary hepatic encephalopathy; Presence of status epilepticus after NAC therapy; History of asthma and anaphylactiod reactions

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
AST. Timepoint: First of the study and 72 hour after treatment. Method of measurement: Serum concentration.;ALT. Timepoint: First of the study and 72 hour after treatment. Method of measurement: Serum concentration.;Bilirubin. Timepoint: First of the study and 72 hour after treatment. Method of measurement: Serum concentration.;Prothrombin time. Timepoint: First of the study and 72 hour after treatment. Method of measurement: Serum concentration.	—

Measure

Time frame

AST. Timepoint: First of the study and 72 hour after treatment. Method of measurement: Serum concentration.;ALT. Timepoint: First of the study and 72 hour after treatment. Method of measurement: Serum concentration.;Bilirubin. Timepoint: First of the study and 72 hour after treatment. Method of measurement: Serum concentration.;Prothrombin time. Timepoint: First of the study and 72 hour after treatment. Method of measurement: Serum concentration.

—

Secondary

Measure	Time frame
Treatment complication. Timepoint: At the first of the study up to 24 hour. Method of measurement: upon history and physical examination during treatment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hamed Pouraziz

Tehran University of Medical Sciences

h-pouraziz@razi.tums.ac.ir+98 21 6640 5588

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026